fatir29 / Shutterstock.com
The Indian government has invited public comments on draft regulatory guidelines for biosimilars, while patent law in this area has still to take shape. Sameer Sah, Nisha Austine and Jahnvi Shah of Khaitan & Co report.
Biologics are large, structurally complex proteins derived from living cells such as bacteria, yeasts or mammalian cells. In comparison to a small molecule or chemical drug, biologics may be 200 to 1,000 times bigger, with high molecular complexity. Biologics include therapeutic proteins and monoclonal antibodies. Biologics that are similar to each other in terms of safety, efficacy and quality to a reference biologic product are referred to as biosimilars.
Due to the complexity of their structures, the discovery process and subsequent manufacturing of biologics is a challenging affair. Even a slight alteration in the composition of a biologic can alter the resulting drug’s efficacy significantly. Comparatively, the discovery process of a biosimilar is bound to be more cost and time effective as the intention is to reproduce and create an almost the same/similar product as the reference biologic, as opposed to creating a completely new product altogether.
While both products retain their complexities in manufacturing, and require robust processes for validation and change control, the reduced expenditure on the discovery process allows biosimilars to be priced more competitively than the reference biologic.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Sameer Sah, Nisha Austine, Jahnvi Shah, Khaitan & Co, patent dance, biosimlars, DCGI, Roche,